236 related articles for article (PubMed ID: 15748964)
1. Follicular lymphoma: time for a re-think?
Gandhi MK; Marcus RE
Blood Rev; 2005 May; 19(3):165-78. PubMed ID: 15748964
[TBL] [Abstract][Full Text] [Related]
2. Indolent lymphomas: current and emerging treatment approaches.
Maloney D; Kahl BS; Dreyling M
Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic advances for indolent lymphomas].
Ogura M
Nihon Rinsho; 2000 Mar; 58(3):682-94. PubMed ID: 10741147
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance.
Cohen Y; Solal-Céligny P; Polliack A
Haematologica; 2003 Jul; 88(7):811-23. PubMed ID: 12857561
[TBL] [Abstract][Full Text] [Related]
5. [Follicular lymphoma].
Illés A; Krenács L; Borbényi Z
Orv Hetil; 2003 Nov; 144(46):2253-61. PubMed ID: 14702920
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
7. Current status and perspective of antibody therapy in follicular lymphoma.
Buske C; Weigert O; Dreyling M; Unterhalt M; Hiddemann W
Haematologica; 2006 Jan; 91(1):104-12. PubMed ID: 16434378
[TBL] [Abstract][Full Text] [Related]
8. Current therapeutic strategies and new treatment paradigms for follicular lymphoma.
Kritharis A; Sharma J; Evens AM
Cancer Treat Res; 2015; 165():197-226. PubMed ID: 25655611
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
10. Follicular lymphoma: a therapeutic update.
Italiano A; Thyss A
Bull Cancer; 2005 Oct; 92(10):E57-64. PubMed ID: 16266867
[TBL] [Abstract][Full Text] [Related]
11. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
[TBL] [Abstract][Full Text] [Related]
12. Current controversies in follicular lymphoma.
Aurora V; Winter JN
Blood Rev; 2006 Jul; 20(4):179-200. PubMed ID: 16410034
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index.
Vose JM; Bierman PJ; Loberiza FR; Lynch JC; Bociek GR; Weisenburger DD; Armitage JO
Biol Blood Marrow Transplant; 2008 Jan; 14(1):36-42. PubMed ID: 18158959
[TBL] [Abstract][Full Text] [Related]
14. Novel antibodies against follicular non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Best Pract Res Clin Haematol; 2011 Jun; 24(2):231-56. PubMed ID: 21658621
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment of follicular lymphoma in the era of monoclonal antibodies.
Coiffier B
Clin Adv Hematol Oncol; 2005 Jun; 3(6):484-91, 505. PubMed ID: 16167027
[TBL] [Abstract][Full Text] [Related]
17. Current management of follicular lymphomas.
Hiddemann W; Buske C; Dreyling M; Weigert O; Lenz G; Unterhalt M
Br J Haematol; 2007 Jan; 136(2):191-202. PubMed ID: 17073892
[TBL] [Abstract][Full Text] [Related]
18. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
Vose J
Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
[TBL] [Abstract][Full Text] [Related]
19. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
20. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]